Profiel
Elizabeth Nguyen worked as a Director-Human Resources Business Partner at InterMune, Inc. and as the Head-Human Resources Business Partnering at MyoKardia, Inc. She then served as the Senior Vice President, Head-Talent & Culture at Surrozen, Inc. Ms. Nguyen holds a graduate degree from Marymount University and an undergraduate degree from Virginia Polytechnic Institute & State University.
Eerdere bekende functies van Elizabeth Nguyen
Bedrijven | Functie | Einde |
---|---|---|
SURROZEN, INC. | Human Resources Officer | 01-07-2023 |
INTERMUNE INC | Human Resources Officer | - |
MYOKARDIA, INC. | Human Resources Officer | - |
Opleiding van Elizabeth Nguyen
Marymount University | Graduate Degree |
Virginia Polytechnic Institute & State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SURROZEN, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |